Syvänne M, Antikainen M, Ehnholm S, Tenkanen H, Lahdenperä S, Ehnholm C, Taskinen M R
Department of Medicine, Helsinki University, Central Hospital, Finland.
J Lipid Res. 1996 Apr;37(4):727-38.
We describe two Finnish kindreds with the Asn291 --> Ser mutation (A291S) of the lipoprotein lipase (LPL) gene. Sixteen subjects (9 male, 7 female) heterozygous for this mutation were studied and compared with 17 unaffected family members or spouses (family controls) and 19 unrelated healthy subjects (population controls). In the group of subjects heterozygous for the A291S mutation, postheparin plasma LPL activity was on average 23% lower than in the family controls and 29% lower than in the population controls. In agreement, in vitro expression studies with COS-7 cells showed that the mutant protein exhibits approximately 50% of the lipolytic activity of the wild-type protein. Median serum triglyceride concentration was 2.90 mmol/l in the group of heterozygotes, compared with 1.14 mmol/l in the family controls (P < 0.01) and 0.99 mmol/l in the population controls (P < 0.001). The heterozygotes also had a marked preponderance of small dense low density lipoproteins (LDL) as assessed by gradient gel electrophoresis. Nine of the heterozygous subjects were hypertriglyceridemic (serum triglyceride concentration > 2.0 mmol/l). Age or body mass index were not related to the presence of hypertriglyceridemia. By contrast, all hypertriglyceridemic subjects were either hyperinsulinemic (serum insulin concentration > 10 mU/l, n = 7) or had diabetes (n = 2). In a multivariate regression analysis, very low density lipoprotein (VLDL) triglyceride level was significantly and independently related to serum apolipoprotein B concentration, the presence of the A291S mutation, serum insulin concentration, and postheparin plasma LPL activity. The Asn291-->Ser mutation of the LPL gene results in reduced lipolytic activity. However, dyslipidemia appears to manifest only if VLDL production is also increased. Hyperinsulinemia was the major determinant of excessive VLDL synthesis and dyslipidemia among the subjects heterozygous for the A291S mutation in this study.
我们描述了两个携带脂蛋白脂肪酶(LPL)基因Asn291→Ser突变(A291S)的芬兰家族。对16名携带该突变的杂合子受试者(9名男性,7名女性)进行了研究,并与17名未受影响的家庭成员或配偶(家族对照)以及19名无关健康受试者(人群对照)进行了比较。在A291S突变杂合子受试者组中,肝素后血浆LPL活性平均比家族对照低23%,比人群对照低29%。与此一致,用COS - 7细胞进行的体外表达研究表明,突变蛋白的脂解活性约为野生型蛋白的50%。杂合子组的血清甘油三酯中位数浓度为2.90 mmol/l,而家族对照为1.14 mmol/l(P < 0.01),人群对照为0.99 mmol/l(P < 0.001)。通过梯度凝胶电泳评估,杂合子还明显以小而密的低密度脂蛋白(LDL)为主。9名杂合子受试者患有高甘油三酯血症(血清甘油三酯浓度>2.0 mmol/l)。年龄或体重指数与高甘油三酯血症的存在无关。相比之下,所有高甘油三酯血症受试者要么高胰岛素血症(血清胰岛素浓度>10 mU/l,n = 7),要么患有糖尿病(n = 2)。在多变量回归分析中,极低密度脂蛋白(VLDL)甘油三酯水平与血清载脂蛋白B浓度、A291S突变的存在、血清胰岛素浓度以及肝素后血浆LPL活性显著且独立相关。LPL基因的Asn291→Ser突变导致脂解活性降低。然而,血脂异常似乎只有在VLDL生成也增加时才会表现出来。在本研究中,高胰岛素血症是A291S突变杂合子受试者中VLDL过度合成和血脂异常的主要决定因素。